During the past decade, UCL Cancer Institute conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 6 clinical trials were completed, i.e. on average, 35.3% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 6 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UCL Cancer Institute" #1 sponsor was "Celgene" with 6 trials, followed by "Janssen Research & Development, LLC" with 4 trials sponsored, "Cancer Research UK" with 3 trials sponsored, "Medical Research Council" with 3 trials sponsored and "University College, London" with 3 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCL Cancer Institute" #1 collaborator was "Medical University Innsbruck" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" with 2 trials as a collaborator, "University College London (UCL) Cancer Institute" with 2 trials as a collaborator and "Universitätsklinikum Hamburg-Eppendorf" with 2 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "UCL Cancer Institute" are "Ovarian Cancer" (5 trials), "Lung Cancer" (4 trials), "Carcinoma, Non-Small-Cell Lung" (3 trials), "Colorectal Cancer" (3 trials) and "Metastatic Cancer" (3 trials). Many other conditions were trialed in "UCL Cancer Institute" in a lesser frequency.

Most popular intervention types in "UCL Cancer Institute" are "Drug" (33 trials), "Procedure" (12 trials), "Other" (9 trials), "Biological" (5 trials) and "Radiation" (5 trials). Other intervention types were less common.

The name of intervention was led by "quality-of-life assessment" (5 trials), "adjuvant therapy" (4 trials), "capecitabine" (4 trials), "laboratory biomarker analysis" (4 trials) and "Amivantamab" (3 trials). Other intervention names were less common.

The vast majority of trials in "UCL Cancer Institute" are 35 trials for "All" genders, 4 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "UCL Cancer Institute". undefined are not yet recruiting, 6 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in UCL Cancer Institute, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in UCL Cancer Institute, 11 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".